Download Medical Notes on The financialisation of Big Pharma

The financialisation of Big Pharma Medical Notes

About This Presentation

Description:The affordability of medicines and access to those is a very hot topic nowadays. One of the main contentions given in the defense of high drug prices is the cost incurred in developing new pharma products. This report examines the role of a financialised pharma business model in justifying the cost of medicines and the profit margins of pharmaceutical companies. The coronavirus COVID-19 pandemic has brought forth the many weak points created by the financialised business model of Big Pharma. This model of Big Pharma has also prevented the world from preparing for the healthcare crisis we are facing today. The rapidly growing debt liabilities of pharmaceutical companies have not been diverted towards developing productive capabilities or getting engaged in R&D. These debt liabilities of pharmaceutical companies have instead been largely distributed to shareholders. Now that the world loo

Tags:Big Pharma, coronavirus, COVID-19, pandemic, healthcare systems, pharmaceutical companies, R&D

Published on: Jun 29, 2020 | Views : 1285 | Downloads : 0

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 3

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 3

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 2

EvaluatePharma Orphan Drug Report 2020

Value of Personalized Medicine

Generics and Biosimilars Industry Response to COVID-19

Pharma 2020 Taxing times ahead

Drug Development with Dutch Public Funding

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019

EvaluatePharma Orphan Drug Report 2020

Orphan Drugs in the United States - Exclusivity, Pricing and Treated Populations

HEALTH A TO Z